Lu-177-DOTATATE is a theranostic radiopharmaceutical that is used for the treatment of neuroendocrine tumors. Using the PRRT (Peptide Receptor Radionuclide Therapy) technique, this radiopharmaceutical binds to neuroendocrine tumor cells quite intelligently and selectively, so it can destroy them thoroughly. Moreover, due to being a gamma emitter, Lu-177-DOTATATE can be used for imaging and the treatment follow-up purposes. Neuroendocrine tumors (NETs) are rare tumors originating from nerve cells and endocrine glands. Neuroendocrine tumors might develop anywhere in the body, including the stomach, intestines, pancreas, or lungs.